Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

The flavonoid luteolin inhibits Fcγ-dependent respiratory burst in granulocytes, but not skin blistering in a new model of pemphigoid in adult mice.

Oswald E, Sesarman A, Franzke CW, Wölfle U, Bruckner-Tuderman L, Jakob T, Martin SF, Sitaru C.

PLoS One. 2012;7(2):e31066. doi: 10.1371/journal.pone.0031066. Epub 2012 Feb 6.

2.

Why human pemphigoid autoantibodies do not trigger disease by the passive transfer into mice?

Sesarman A, Oswald E, Chiriac MT, Csorba K, Vuta V, Feldrihan V, Baican A, Bruckner-Tuderman L, Sitaru C.

Immunol Lett. 2012 Mar 30;143(1):92-100. doi: 10.1016/j.imlet.2012.01.006. Epub 2012 Jan 25.

PMID:
22305931
3.

Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study.

Di Zenzo G, Thoma-Uszynski S, Calabresi V, Fontao L, Hofmann SC, Lacour JP, Sera F, Bruckner-Tuderman L, Zambruno G, Borradori L, Hertl M.

J Invest Dermatol. 2011 Nov;131(11):2271-80. doi: 10.1038/jid.2011.180. Epub 2011 Jun 23.

4.

A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen.

Ujiie H, Shibaki A, Nishie W, Sawamura D, Wang G, Tateishi Y, Li Q, Moriuchi R, Qiao H, Nakamura H, Akiyama M, Shimizu H.

J Immunol. 2010 Feb 15;184(4):2166-74. doi: 10.4049/jimmunol.0903101. Epub 2010 Jan 20.

5.

A novel humanized neonatal autoimmune blistering skin disease model induced by maternally transferred antibodies.

Nishie W, Sawamura D, Natsuga K, Shinkuma S, Goto M, Shibaki A, Ujiie H, Olasz E, Yancey KB, Shimizu H.

J Immunol. 2009 Sep 15;183(6):4088-93. doi: 10.4049/jimmunol.0800389. Epub 2009 Aug 28.

6.

Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study.

Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, Hohl D, Itin P, Lautenschlager S, Naldi L, Borradori L; Autoimmune bullous disease Swiss study group.

Br J Dermatol. 2009 Oct;161(4):861-8. doi: 10.1111/j.1365-2133.2009.09300.x. Epub 2009 May 8.

PMID:
19566661
7.

Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model.

Liu Z, Sui W, Zhao M, Li Z, Li N, Thresher R, Giudice GJ, Fairley JA, Sitaru C, Zillikens D, Ning G, Marinkovich MP, Diaz LA.

J Autoimmun. 2008 Dec;31(4):331-8. doi: 10.1016/j.jaut.2008.08.009. Epub 2008 Oct 14.

8.

Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.

Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J.

BMJ. 2008 Jul 9;337:a180. doi: 10.1136/bmj.a180.

9.

Immune thrombocytopenic purpura--from agony to agonist.

Schwartz RS.

N Engl J Med. 2007 Nov 29;357(22):2299-301. No abstract available.

PMID:
18046034
10.

The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita.

Mihai S, Chiriac MT, Takahashi K, Thurman JM, Holers VM, Zillikens D, Botto M, Sitaru C.

J Immunol. 2007 May 15;178(10):6514-21.

11.

NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage.

Chiriac MT, Roesler J, Sindrilaru A, Scharffetter-Kochanek K, Zillikens D, Sitaru C.

J Pathol. 2007 May;212(1):56-65.

PMID:
17380558
12.

Humanization of autoantigen.

Nishie W, Sawamura D, Goto M, Ito K, Shibaki A, McMillan JR, Sakai K, Nakamura H, Olasz E, Yancey KB, Akiyama M, Shimizu H.

Nat Med. 2007 Mar;13(3):378-83. Epub 2007 Feb 25.

PMID:
17322897
13.

Role of different pathways of the complement cascade in experimental bullous pemphigoid.

Nelson KC, Zhao M, Schroeder PR, Li N, Wetsel RA, Diaz LA, Liu Z.

J Clin Invest. 2006 Nov;116(11):2892-900. Epub 2006 Oct 5.

14.

Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice.

Sitaru C, Chiriac MT, Mihai S, Büning J, Gebert A, Ishiko A, Zillikens D.

J Immunol. 2006 Sep 1;177(5):3461-8.

15.

Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen.

Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B, Saito H, Rose C, Ishiko A, Zillikens D.

J Clin Invest. 2005 Apr;115(4):870-8.

16.

Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura.

HARRINGTON WJ, MINNICH V, HOLLINGSWORTH JW, MOORE CV.

J Lab Clin Med. 1951 Jul;38(1):1-10. No abstract available.

PMID:
14850832
17.

BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid.

Kobayashi M, Amagai M, Kuroda-Kinoshita K, Hashimoto T, Shirakata Y, Hashimoto K, Nishikawa T.

J Dermatol Sci. 2002 Dec;30(3):224-32.

PMID:
12443845
18.

Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin.

Sitaru C, Schmidt E, Petermann S, Munteanu LS, Bröcker EB, Zillikens D.

J Invest Dermatol. 2002 Apr;118(4):664-71.

19.

Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid.

Yamamoto K, Inoue N, Masuda R, Fujimori A, Saito T, Imajoh-Ohmi S, Shinkai H, Sakiyama H.

J Invest Dermatol. 2002 Mar;118(3):485-92.

20.

A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.

Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, Vaillant L, D'Incan M, Plantin P, Bedane C, Young P, Bernard P; Bullous Diseases French Study Group.

N Engl J Med. 2002 Jan 31;346(5):321-7.

Supplemental Content

Support Center